Showing 1,401 - 1,420 results of 2,017 for search '(( significant decrease decrease ) OR ( significantly declined decrease ))~', query time: 0.34s Refine Results
  1. 1401

    Image 6_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Mortality and DALYs declined significantly, with age-standardized mortality rates (ASMR) and DALYs rates (ASDR) decreasing by 50.0 and 36.3%, respectively. …”
  2. 1402

    Image 1_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Mortality and DALYs declined significantly, with age-standardized mortality rates (ASMR) and DALYs rates (ASDR) decreasing by 50.0 and 36.3%, respectively. …”
  3. 1403

    Image 3_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.tiff by Zilun Wu (18696883)

    Published 2025
    “…Mortality and DALYs declined significantly, with age-standardized mortality rates (ASMR) and DALYs rates (ASDR) decreasing by 50.0 and 36.3%, respectively. …”
  4. 1404

    Table 1_Screening of strawberry (Fragaria × ananassa Duch.) cultivars for drought tolerance based on physiological and biochemical responses under PEG-induced stress.docx by Şule Hilal Attar (22245970)

    Published 2025
    “…In contrast, 'Calderon' and 'Plared' showed significant declines in physiological performance. The study reveals cultivar-specific drought response strategies, with sugar accumulation, chlorophyll stability, and antioxidant capacity serving as reliable screening markers. …”
  5. 1405

    Data Sheet 1_Global burden of varicella and herpes zoster across 204 countries, 1990–2021: a temporal trend analysis in the era of the COVID-19 pandemic and projections to 2036.pdf... by Zilun Wu (18696883)

    Published 2025
    “…Mortality and DALYs declined significantly, with age-standardized mortality rates (ASMR) and DALYs rates (ASDR) decreasing by 50.0 and 36.3%, respectively. …”
  6. 1406

    Data Sheet 1_Particulate matter pollution and older adult health: global trends and disparities, 1991–2021.docx by Qiong Yi (3931826)

    Published 2024
    “…However, age-standardized mortality rate decreased from 384 to 337 per 100,000. HAP-SF-related deaths decreased from 2,700,000 to 2,100,000, and DALYs from 54,000,000 to 42,000,000. …”
  7. 1407

    Supplementary Material for: Retrospective Analysis of Allergen Characteristics in Patients with Allergic Diseases in Sanmen, Zhejiang Province by figshare admin karger (2628495)

    Published 2025
    “…The positivity rate for serum total IgE was 25.67%, significantly higher than the IgE prevalence of inhalant allergens (24.84%) and food allergens (12.48%), significantly higher than the positivity rate for food allergen sIgE at 12.48% (P<0.001). …”
  8. 1408

    Regional differences in cholinergic sweating in the lower limb by Tatsuro Amano (19855662)

    Published 2025
    “…Sweat rate at the forearm (all <i>P</i> ≥ 0.265) and foot (all <i>P</i> ≥ 0.077) did not differ significantly across age groups. However, thigh sweat rate declined with age: reductions were observed in the posterior thigh from the 50s (<i>P</i> ≤ 0.004) and in the anterior thigh in the 60s (<i>P</i> ≤ 0.036). …”
  9. 1409

    DataSheet1_Positive vaccine beliefs linked to reduced mental stress in healthcare professionals during COVID-19: a retrospective study.pdf by Yu-Yin Lin (19690501)

    Published 2024
    “…However, the scores and the percentage of moderate to severe burnout gradually decreased. Notably, the percentage of individuals with moderate to severe mood disorders also gradually declined (2020: 13.4%, 2021: 12.3%, 2022: 11.1%). …”
  10. 1410

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  11. 1411

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  12. 1412

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  13. 1413

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  14. 1414

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  15. 1415

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  16. 1416

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  17. 1417

    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  18. 1418

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  19. 1419

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  20. 1420

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”